Intestinal permeability enhancement: structure-activity and structure-toxicity relationships for nonylphenoxypolyoxyethylene surfactant permeability enhancers.
Swenson
E S
ES
Pharmaceutical R&D Department, Central Research Division, Pfizer Inc., Groton Connecticut 06340.
Milisen
W B
WB
Curatolo
W
W
D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D066298:In Vitro Techniques; D007408:Intestinal Absorption / Q000187:drug effects*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D007421:Intestine, Small / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D010637:Phenolsulfonphthalein / Q000493:pharmacokinetics; D010743:Phospholipids / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D013268:Stimulation, Chemical; D013329:Structure-Activity Relationship; D013501:Surface-Active Agents / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity
D010743:Phospholipids; D013501:Surface-Active Agents; C091962:nonylphenoxypolyoxyethylene; D011092:Polyethylene Glycols; D007770:L-Lactate Dehydrogenase; D010637:Phenolsulfonphthalein